Berlin-Chemie Menarinis’s journey in Uzbekistan is a 28-year story of passion and professionalism, one that continues to evolve and thrive.

Thanks to its deep commitment to this Central Asian region, Berlin-Chemie Menairni has become a key player in Uzbekistan’s pharmaceutical market, strategically positioned along the historic Silk Road.

In 2024, the company revenue exceeded 40 million €; this milestone was supported by a diverse portfolio of products addressing multiple therapeutic areas, with a particular focus on expanding its offerings in cardiology.

While 70% of sales stem from prescription medications, the Consumer Healthcare segment has also experienced significant growth, fueled by the popularity of flagship products that have become staples in the market.

A key driver of success in Uzbekistan has been the company’s dedicated medical representatives. These professionals not only ensure consistent growth but also play a vital role in keeping healthcare providers informed and up-to-date with the latest advancements.

Another standout initiative is the Berlin-Chemie Academy, a comprehensive healthcare education program which spans across the regional Central and Eastern Europe as well as Central Asia and is managed through the regional headquarters in Berlin. It offers interdisciplinary training through live webinars, on-demand sessions, and supplementary resources.

The Academy focuses on key areas such as cardiometabolic health, pain management, and thyroid conditions. These sessions have gained widespread recognition, drawing numerous top-tier specialists annually who value the insightful and practical content provided.

Berlin-Chemie Menarinis’s extensive efforts over the years demonstrate that dedication and innovation are the foundation of lasting success. By continuing to invest in Uzbekistan’s healthcare sector, the company is helping to build a brighter, healthier future for the region.